SCHEMBL1490897

SCHEMBL1490897

CC(O)SC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 7/20 0.76
NADK O95544 1/20 0.76
DOT1L Q8TEK3 3/20 0.69
PNMT P11086 1/20 0.69
DNMT1 P26358 1/20 0.69
DNMT3B Q9UBC3 1/20 0.69
DPP4 P27487 1/20 0.69
MEN1 O00255 1/20 0.69
SLC28A1 O00337 1/20 0.69
MAP3K7 O43318 1/20 0.69
SLC28A2 O43868 1/20 0.69
GAPDH P04406 1/20 0.69
ADORA3 P0DMS8 1/20 0.69
MAPK1 P28482 1/20 0.69
ADORA2A P29274 1/20 0.69
ADORA2B P29275 1/20 0.69
ADORA1 P30542 1/20 0.69
STAT6 P42226 1/20 0.69
PI4KA P42356 1/20 0.69
KMT2A Q03164 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6935387 0.93 AHCY (0.78) AHCYNADKDOT1LPNMTDNMT1
SCHEMBL8943648 0.91 AHCY (0.74) AHCYNADKDOT1LPNMTDNMT1
SCHEMBL8943736 0.91 AHCY (0.74) AHCYNADKDOT1LPNMTDNMT1
SCHEMBL8943568 0.91 AHCY (0.74) AHCYNADKDOT1LPNMTDNMT1
SCHEMBL3488878 0.88 AHCY (0.78) AHCYNADKDOT1LPNMTDNMT1
SCHEMBL5055541 0.87 AHCY (0.76) AHCYNADKDOT1LPNMTDNMT1
Methylthioadenosine SCHEMBL10013421 0.87 AHCY (0.83) AHCYNADKDOT1LPNMTDNMT1
Methylthioadenosine SCHEMBL11954365 0.87 AHCY (0.83) AHCYNADKDOT1LPNMTDNMT1
Methylthioadenosine SCHEMBL20798030 0.87 AHCY (0.83) AHCYNADKDOT1LPNMTDNMT1
Methylthioadenosine SCHEMBL890628 0.87 AHCY (0.83) AHCYNADKDOT1LPNMTDNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0555352-A4 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH INC (US) 1994-12-14 EP claimed
EP-0555352-A1 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH, INC. (US) 1993-08-18 EP claimed
US-5180714-A ADENOSINE COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA HEALTH RESEARCH, INC. (US) 1993-01-19 US claimed
WO-1992007570-A1 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH, INC. (US) 1992-05-14 WO claimed
US-9174960-B2 Compounds useful against kinetoplastideae parasites CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-11-03 US disclosed
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-08-23 US disclosed
EP-2477698-A2 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES Centre National de la Recherche Scientifique (FR) 2012-07-25 EP disclosed
WO-2011033115-A2 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-24 WO disclosed
US-5563125-A 5'-deoxy-5'-(substituted)alkylthioribose compounds and their pharmaceutical compositions HEALTH RESEARCH, INC. (US) 1996-10-08 US disclosed
US-5563125-A 5'-deoxy-5'-(substituted)alkylthioribose compounds and their pharmaceutical compositions HEALTH RESEARCH, INC. (US) 1996-10-08 US disclosed
EP-0555352-A4 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH INC (US) 1994-12-14 EP disclosed
EP-0555352-A1 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH, INC. (US) 1993-08-18 EP disclosed
EP-0555352-A1 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH, INC. (US) 1993-08-18 EP disclosed
US-5180714-A ADENOSINE COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA HEALTH RESEARCH, INC. (US) 1993-01-19 US disclosed
US-5180714-A ADENOSINE COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA HEALTH RESEARCH, INC. (US) 1993-01-19 US disclosed
WO-1992007570-A1 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH, INC. (US) 1992-05-14 WO disclosed
WO-1992007570-A1 AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES HEALTH RESEARCH, INC. (US) 1992-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES TST, PDXK, TBCB AHCY 2736/4885NADK 99/4885DOT1L 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.